Skip to main content
Premium Trial:

Request an Annual Quote

Upstate, Michael Kelly, Jim Woodgett


New Products

Upstate has released a new Beadlyte 8-plex multi-pathway signaling kit, Phosphoprotein. The kit enables researchers to perform simultaneous quantitative detection of multiple cell signaling pathways in a single 5µl (5µg) cell lysate sample, according to Upstate. Phosphoproteins measured include key markers of receptor tyrosine kinase, stress induction, and death receptor pathways.

Movers & Shakers

ViaLogy, a provider of signal-processing software for analyzing data from microarrays, mass spectrometers, and other instrument platforms, has hired Michael Kelly as its CEO and president. Kelly is a general partner and manager at the Palo Alto office of First Ventury, a venture capital firm. Before joining First Ventury, Kelly was CEO of American Express Bank GmbH, Frankfurt, and senior banker with Commerzbank and Bank of America in the US and Deutsche Bank in Germany.

Jim Woodgett has been named the new director of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto, the hospital said last week.

Woodgett previously served as director of the University Health Network's Microarray Center. He has also been division head of experimental therapeutics at the Ontario Cancer Institute at Princess Margaret Hospital in Toronto.